AVR · Anteris Technologies Global Corp. · Stock research

Current Thesis

Anteris is a clinical-stage structural-heart company, dual-listed ASX:AVR / NASDAQ:AVR, built around DurAVR — a single-piece, 3D-shaped biomimetic transcatheter aortic valve now enrolling the US-pivotal PARADIGM trial (~1,000 patients, 1:1 versus commercially available TAVR, non-inferiority on a composite of all-cause mortality, all stroke and cardiovascular hospitalization at one year). The de-risking sequence that powered the run is spent: CMS Coverage-with-Evidence-Development under NCD 20.32 (April 2026), first US patients treated (May 2026), French and Canadian regulatory clearance. The 2026-08-11 Q2 report added execution detail but no data: EPS $(0.30) against a $(0.21) consensus, revenue $1.009M against $1.500M consensus, net operating cash outflow $20.8M, R&D $23.4M. The tape absorbed it — the 2026-08-14 close was $9.40 with RSI(14) at 66.9 and the name 11.1% below its $10.57 52-week high, a three-month return of +29.8%. What is being bought here is an enrollment-progress story with a 2028 payoff, held up by sell-side targets (Cantor reiterated Overweight, PT $15, on 2026-08-14) and sitting directly on top of a live $250M at-the-market shelf priced off $9.00. maturing: well known to its holders, still working, no new attention since the June clearances, and the next hard datapoint is years out.

Bullish and bearish views on Anteris Technologies Global Corp.

The model's bull view on Anteris Technologies Global Corp. (AVR), in brief: Enrollment is geographically live, not theoretical. The bear view: The $250M ATM is an in-the-money seller at the exact level price is standing on. Both cases follow in full.

Bull Case

• Enrollment is geographically live, not theoretical. The 2026-08-11 Q2 release lists active recruitment in the US, Denmark and the Netherlands, with regulatory clearance obtained in Canada and France and Australian sites pending ethics-committee approval. Expanding site count is the only operational metric that can be marked before 2027.
• Reimbursement was cleared ahead of the ramp. CMS Coverage-with-Evidence-Development under TAVR NCD 20.32 secured April 2026; first US patients enrolled and treated May 2026 — trial procedures are Medicare-eligible, removing the largest US execution obstacle.
• Incumbent capital is inside the cap table. Covidien (Medtronic subsidiary) committed up to $90M for 16–19.99% of post-offering shares, closing 2026-01-22 alongside a $230M public raise, $320M aggregate.
• Coverage has not blinked through a double miss. Cantor Fitzgerald reiterated Overweight with a $15 target on 2026-08-14, two sessions after the Q2 miss, against a $9.40 close. Prior standing targets: Barclays Overweight $18 (2026-05-15), Wells Fargo Overweight $16 (2026-03-11).
• Burn stepped down sequentially. Net operating cash outflow was $20.8M in Q2 2026 against roughly $28.7M in the Q1 outflow, while R&D ran $23.4M — spend directed into trial and manufacturing scale-up rather than commercial infrastructure.

Bear Case

• The $250M ATM is an in-the-money seller at the exact level price is standing on. The TD Securities sales agreement dated 2026-05-22 references $9.00 at 3.0% commission, roughly 26–28M shares against a ~97M count. Above $9.00 the company can manufacture supply at will; the 2026-08-14 close of $9.40 sits 4% over that line.
• Q2 missed on both lines. EPS $(0.30) versus $(0.21) estimate, revenue $1.009M versus $1.500M estimate (2026-08-12 reporting). Revenue did rise from $494K in Q1 2026, but at $1.009M against $23.4M of quarterly R&D the sales line is not yet an input to anything.
• No dated binary inside the window. PARADIGM's one-year primary endpoint sits around 2028 with enrollment completion guided toward ~Q1 2027. Between now and then the news flow is site activations and cash reports — enrollment-pace items, not evidence about the valve.
• Positioning is thin and single-name. No small-cap TAVR cohort is moving alongside it; the listed comparables (EW, MDT, BSX) are mega-caps. A GuruFocus item headlined an L1 Capital trim of the AVR stake "amid strong rally" circulated; neither size nor date could be confirmed for this note, and the ASX substantial-holder notices are where a reader verifies it.
• The 2025 loss run-rate is the backdrop: net loss $94.14M on $1.91M revenue for FY2025.

Setup & Price Structure

Last completed daily close $9.40 (2026-08-14), 11.1% under the $10.57 52-week high, +29.8% over three months, RSI(14) 66.9. The structure is a recovery leg inside a range whose floor is the $9.00 ATM reference and whose ceiling is the July high — momentum elevated near 67 on RSI while price is still more than a tenth below the high describes a bounce that has not retested the top. Holding $9.40 within two sessions of a double miss suggests the print was already discounted; that is an inference from tape behaviour, not from any disclosed flow. The observable crowding evidence: a standing $250M issuance facility in the money, an earnings event now behind the name (no scheduled print for roughly three months), and coverage clustered on Overweight ratings well above spot with no data event to mark them against. Reclaiming $10.57 on a weekly closing basis would be the first genuinely new price information since June.

Catalyst Calendar (next 30 days)

• No confirmed company event falls inside 2026-08-16 → 2026-09-15. The Q2 print (2026-08-11 release, 2026-08-12 reporting) has elapsed; the ASX Appendix 4C for the June quarter has elapsed.
• ~2026-10-31 (est.) — ASX Appendix 4C quarterly cash-flow report for the September quarter; the cleanest read on ATM draw pace and burn.
• ~2026-11-12 (est.) — Q3 2026 results (Q1 landed 2026-05-12, Q2 2026-08-11).
• ~Q1 2027 (company framing) — PARADIGM enrollment completion; ~2028 — one-year primary endpoint.

Elapsed catalysts

• ~Q4 2026 (est.) — first Australian PARADIGM site activation, explicitly gated on ethics-committee approval per the 2026-08-11 release. Undated by the company. (passed 15d ago)

What Would Change Our Mind

The structure that breaks first is the $9.00 shelf the ATM is priced off: losing it turns the facility from a ceiling into a source of supply chasing price down and marks the July–August recovery as a failed retest. A weekly close below $9.00 is the gradeable version of that. Second condition: an 8-K, prospectus supplement or Appendix 4C disclosing heavy issuance under the TD Securities facility into this strength — the company selling its own shelf in the $9s would answer the question of who has been bidding. Third: any PARADIGM enrollment suspension, DSMB action or clinicaltrials.gov status change, which removes the only asset the story owns. On the other side, a weekly close above $10.57 with a dated site-expansion or enrollment milestone behind it would re-classify the leg as accelerating rather than drifting.

Correlation Notes

• Dual listing drives the open. ASX:AVR trades ahead of the US session; ASX announcements and Appendix 4C filings land before the NASDAQ tape can price them.
• No theme cluster. This is not an AI, power or semis basket name and it does not move with index momentum factors. The nearest comparables (Edwards Lifesciences, Medtronic, Boston Scientific) are mega-cap incumbents whose TAVR franchises are already commercial; their prints do not mark AVR to market.
• Pre-revenue duration risk. With no earnings to discount and burn above $20M/quarter, the name behaves like small-cap clinical medtech: sensitive to rate expectations and to risk appetite in the unprofitable-healthcare complex rather than to structural-heart procedure volumes.
• The Medtronic relationship cuts both ways. Covidien is a large holder via the January 2026 raise and Medtronic is the incumbent competitor; a change in that holding, disclosed via a 13D/G amendment, would be read as a statement about the valve.